ReviewAnnals of medicine2026
Imbalance of mitochondria and abnormalities in lipid metabolism in Diabetic Tubulopathy.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a common and serious microvascular complication in patients with diabetes. In recent years, diabetic tubulopathy has emerged as a major research focus, as its prognosis is closely associated with tubular atrophy and interstitial fibrosis. Multiple studies indicate that diabetes directly damages renal tubules, leading to mitochondrial dysfunction-characterized by impaired mitochondrial bioenergetics, excessive mitochondrial reactive oxygen species (mtROS) production, defective autophagy, and lipid metabolism disorders resulting from abnormal lipid accumulation. Consequently, this cascade triggers a series of metabolic abnormalities. However, the precise mechanisms underlying renal tubular mitochondrial dysfunction and the regulatory pathways of lipid metabolism disorders remain incompletely elucidated. A deeper understanding of the pathobiology of the tubulointerstitium will facilitate the discovery of novel biomarkers for DKD. Based on current literature, this review proposes that mitochondrial dysfunction and abnormal lipid metabolism may accelerate early-stage diabetic tubulopathy, thereby potentially improving patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.